LBA25 Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial

Authors:
  • YVY. Vano
    Y. Vano
  • RER.T. Elaidi
    R.T. Elaidi
  • MBM. Bennamoun
    M. Bennamoun
  • CCC.M. Chevreau
    C.M. Chevreau
  • DBD. Borchiellini
    D. Borchiellini
  • DPD. Pannier
    D. Pannier
  • DMD. Maillet
    D. Maillet
  • MGM. Gross-Goupil
    M. Gross-Goupil
  • CTC. Tournigand
    C. Tournigand
  • BLB. Laguerre
    B. Laguerre
  • PBP. Barthélémy
    P. Barthélémy
  • FJF. Joly
    F. Joly

Abstract
No abstract available